» Articles » PMID: 20017672

TaqMan Low-density Arrays and Analysis by Artificial Neuronal Networks Predict Response to Neoadjuvant Chemoradiation in Esophageal Cancer

Overview
Specialties Genetics
Pharmacology
Date 2009 Dec 19
PMID 20017672
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Neoadjuvant radiochemotherapy of locally advanced esophageal cancer is only effective for patients with major histopathological response. A total of 17 genes were selected to predict histopathologic tumor response to chemoradiation (cisplatin, 5-fluorouracil, 36 Gy).

Materials & Methods: For gene-expression analysis quantitative TaqMan low-density arrays were applied. Expression levels in pretreatment biopsies of 41 patients (cT2-4, Nx, M0) were compared with the degree of histopathologic regression in resected specimens applying univariate, multivariate and artificial neuronal network analyses.

Results: Dihydropyrimidine dehydrogenase was identified as an independent predictor associated with major response (p < 0.002). Multivariate analysis of the marker combination provided response prediction with 75.0% sensitivity, 81.0% specificity and 78.1% accuracy. Artificial neuronal network analysis was the best predictive model for major histopathologic response (80% sensitivity, 90.5% specificity and 85.4% accuracy), representing a clinically practical system.

Conclusion: Low-density-array RT-PCR analyzed by artificial neuronal network predicts histopathologic response to neoadjuvant chemoradiation in our patient collective, and could be used to further individualize treatment strategies in esophageal cancer.

Citing Articles

Artificial intelligence in esophageal cancer diagnosis and treatment: where are we now?-a narrative review.

Merchan Gomez B, Milla Collado L, Rodriguez M Ann Transl Med. 2023; 11(10):353.

PMID: 37675332 PMC: 10477654. DOI: 10.21037/atm-22-3977.


Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma.

Jiang W, de Jong J, van Hillegersberg R, Read M Cancers (Basel). 2022; 14(4).

PMID: 35205743 PMC: 8869950. DOI: 10.3390/cancers14040996.


Towards Personalized Treatment Strategies for Esophageal Adenocarcinoma; A Review on the Molecular Characterization of Esophageal Adenocarcinoma and Current Research Efforts on Individualized Curative Treatment Regimens.

Hoefnagel S, Boonstra J, Russchen M, Krishnadath K Cancers (Basel). 2021; 13(19).

PMID: 34638363 PMC: 8508226. DOI: 10.3390/cancers13194881.


Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer.

Lavery A, Turkington R Gastroenterol Rep (Oxf). 2021; 8(6):411-424.

PMID: 33442473 PMC: 7793050. DOI: 10.1093/gastro/goaa065.


Artificial intelligence-assisted esophageal cancer management: Now and future.

Zhang Y, Guo L, Yuan X, Hu B World J Gastroenterol. 2020; 26(35):5256-5271.

PMID: 32994686 PMC: 7504247. DOI: 10.3748/wjg.v26.i35.5256.